Articles
After receiving Fast Track designation from the U.S. FDA to expedite review of their anti-inflammatory treatment in a Phase II study, a large pharmaceutical sponsor sought support for a comprehensive solution spanning translational biomarkers, gene expression and data analysis for their asset in late-stage clinical development.